SCHEMBL30714564

SCHEMBL30714564

Cn1nccc1COc1ccc2nn(C)c(C(=O)NC(C)(C)CO)c2c1

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 11/20 0.38
CNR2 P34972 11/20 0.38
HPGDS O60760 1/20 0.37
SCN9A Q15858 1/20 0.35
CYP11B2 P19099 1/20 0.35
KDM4C Q9H3R0 1/20 0.35
HDAC1 Q13547 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
KMT2A Q03164 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MCHR1 Q99705 2/20 0.34
KDM4E B2RXH2 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30714615 0.92 HPGDS (0.37) HPGDSCYP11B2KDM4CHDAC1HDAC8
SCHEMBL30714580 0.89 CYP11B2 (0.37) HPGDSCYP11B2KDM4CHDAC1HDAC8
SCHEMBL30714704 0.87 HPGDS (0.38) CNR2HPGDSCYP11B2KDM4CKMT2A
SCHEMBL30714708 0.84 EGLN2 (0.47) CNR1CNR2HDAC1HDAC8HDAC6
SCHEMBL26696010 0.83 HPGDS (0.41) HPGDSCYP11B2KDM4CKMT2AL3MBTL1
SCHEMBL26696001 0.82 KDM4C (0.41) HPGDSCYP11B2KDM4CKMT2AL3MBTL1
SCHEMBL30714642 0.81 HPGDS (0.36) HPGDSSCN9ACYP11B2KDM4CKMT2A
SCHEMBL30714582 0.81 CNR2 (0.37) CNR1CNR2MCHR1
SCHEMBL30714617 0.80 CYP11B2 (0.37) CNR1CNR2HPGDSSCN9ACYP11B2
SCHEMBL30714559 0.80 CNR1 (0.36) CNR1CNR2SCN9AMCHR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
CN-119968362-A Indazole derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-05-09 CN disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 CNR1 271/4885CNR2 107/4885HPGDS 671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.